BR112022009204A2 - Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70 - Google Patents

Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70

Info

Publication number
BR112022009204A2
BR112022009204A2 BR112022009204A BR112022009204A BR112022009204A2 BR 112022009204 A2 BR112022009204 A2 BR 112022009204A2 BR 112022009204 A BR112022009204 A BR 112022009204A BR 112022009204 A BR112022009204 A BR 112022009204A BR 112022009204 A2 BR112022009204 A2 BR 112022009204A2
Authority
BR
Brazil
Prior art keywords
rcc
cell carcinoma
renal cell
therapy
genetically manipulated
Prior art date
Application number
BR112022009204A
Other languages
English (en)
Inventor
Alexander Terrett Jonathan
Dequéant Mary-Lee
Will Matthias
Original Assignee
Crispr Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crispr Therapeutics Ag filed Critical Crispr Therapeutics Ag
Publication of BR112022009204A2 publication Critical patent/BR112022009204A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Abstract

TERAPIA DE CARCINOMA DE CÉLULAS RENAIS (RCC) USANDO CÉLULAS T GENETICAMENTE MANIPULADAS VISANDO CD70. A presente invenção refere-se a invenção composições compreendendo uma população de células T geneticamente manipuladas que expressam um receptor de antígeno quimérico (CAR) que se liga a CD70 e métodos de uso das mesmas para o tratamento de carcinoma de células renais (RCC).
BR112022009204A 2019-11-13 2020-11-13 Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70 BR112022009204A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934961P 2019-11-13 2019-11-13
US202063034552P 2020-06-04 2020-06-04
PCT/IB2020/060719 WO2021095010A1 (en) 2019-11-13 2020-11-13 Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70

Publications (1)

Publication Number Publication Date
BR112022009204A2 true BR112022009204A2 (pt) 2022-07-26

Family

ID=73695085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009204A BR112022009204A2 (pt) 2019-11-13 2020-11-13 Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70

Country Status (11)

Country Link
US (1) US20220387572A1 (pt)
EP (1) EP4058053A1 (pt)
JP (1) JP2023501602A (pt)
KR (1) KR20220100913A (pt)
CN (1) CN114929267A (pt)
AU (1) AU2020383021A1 (pt)
BR (1) BR112022009204A2 (pt)
CA (1) CA3158110A1 (pt)
IL (1) IL292468A (pt)
MX (1) MX2022005821A (pt)
WO (1) WO2021095010A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022238963A2 (en) * 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating solid tumors
WO2023072307A1 (zh) * 2021-10-25 2023-05-04 重庆精准生物技术有限公司 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用
CN117844811A (zh) * 2024-03-08 2024-04-09 上海恒润达生生物科技股份有限公司 靶向敲除CD70基因的sgRNA组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018007263A1 (en) * 2016-07-06 2018-01-11 Cellectis Sequential gene editing in primary immune cells
EP3621981A2 (en) 2017-05-12 2020-03-18 CRISPR Therapeutics AG Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2019152742A1 (en) * 2018-02-01 2019-08-08 Pfizer Inc. Chimeric antigen receptors targeting cd70
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer

Also Published As

Publication number Publication date
EP4058053A1 (en) 2022-09-21
MX2022005821A (es) 2022-08-16
AU2020383021A1 (en) 2022-05-19
US20220387572A1 (en) 2022-12-08
CA3158110A1 (en) 2021-05-20
JP2023501602A (ja) 2023-01-18
KR20220100913A (ko) 2022-07-18
IL292468A (en) 2022-06-01
WO2021095010A1 (en) 2021-05-20
CN114929267A (zh) 2022-08-19

Similar Documents

Publication Publication Date Title
BR112022009204A2 (pt) Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
BR112022009290A2 (pt) Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70
BR112018067679A2 (pt) células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
BR112017003104A2 (pt) tratamento de câncer usando um receptor antigênico quimérico anti-cd123
BR112021021843A2 (pt) Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas
CL2019000760A1 (es) Tratamiento de migraña refractaria
MX2020012927A (es) Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular.
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
BR112017000939A2 (pt) tratamento de câncer usando um receptor antigênico quimérico de cll-1
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112018070636A2 (pt) método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
BR112018003308A2 (pt) receptor quimérico de citocina
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
BR112022009141A2 (pt) Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
BR112018073136A2 (pt) métodos para tratar doença autoimune usando células t alogênicas
BR112021026382A2 (pt) Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer
MX2020012613A (es) Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]